Nano Pharmaceuticals
Market Cap
₹7 ₹7.00 Cr.
P/E
0.00
PEG = P/E ÷ 5yr Forward EPS CAGR

The forward EPS CAGR is estimated individually for each company - factoring in its guidance, industry, and growth drivers - not generic rule-based projection.

  • Hind Bio Sciences
  • Hemo Organic
  • Ganga Pharma

FAQs on Hindustan Bio Sciences Ltd. Shareprice

Hind Bio Sciences has given better returns compared to its competitors.
Hind Bio Sciences has grown at ~32.63% over the last 9yrs while peers have grown at a median rate of 5.79%

Hind Bio Sciences is not expensive.
Latest PE of Hind Bio Sciences is 0, while 3 year average PE is 96.73.
Also latest EV/EBITDA of Hind Bio Sciences is 0.0 while 3yr average is 308.

Growth Table

  • Hindustan Bio Sciences Ltd.
  • Hemo Organic
  • Ganga Pharma

Balance Sheet

  • Hindustan Bio Sciences Ltd.
  • Hemo Organic
  • Ganga Pharma

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Hindustan Bio Sciences Ltd.
  • Hemo Organic
  • Ganga Pharma

Cash Flow

  • Hindustan Bio Sciences Ltd.
  • Hemo Organic
  • Ganga Pharma

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Hindustan Bio Sciences Ltd.
  • Hemo Organic
  • Ganga Pharma

Quarterly Results

  • Hindustan Bio Sciences Ltd.
  • Hemo Organic
  • Ganga Pharma

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*

FAQs on Hindustan Bio Sciences Ltd. Financials

Hind Bio Sciences balance sheet is weak and might have solvency issues

The net debt of Hind Bio Sciences is decreasing.
Latest net debt of Hind Bio Sciences is ₹2.22 Crs as of Mar-26.
This is less than Mar-25 when it was ₹2.48 Crs.

Yes, profit is increasing.
The profit of Hind Bio Sciences is ₹0.1 Crs for Mar 2025, ₹0.06 Crs for Mar 2024 and -₹0.04 Crs for Mar 2023

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Hind Bio Sciences latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

Companies resources are allocated to majorly unproductive assets like Short Term Loans & Advances

Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech